-
The CSCO annual meeting will be held in 2021. Roche's latest blood product R&D pipeline is "exposed", creating a new pattern for lymphoma treatment
Time of Update: 2021-10-11
The recently announced global multi-center Phase III Polarix study included 879 newly-treated DLBCL patients who received 6 cycles of Pola combined with R-CHP (rituximab, ring Phosphoramide, doxorubicin, prednisone) treatment, or 6 cycles of R-CHOP regimen treatment group, followed by 2 cycles of rituximab treatment .
-
2021 CSCO WuXi Juno Satellite Symposium: Based on China, forging ahead, Benoda® helps patients benefit from long-term survival
Time of Update: 2021-10-11
The RELIANCE study confirmed that patients with CR at 3 months can achieve long-term remission, and the 1-year overall survival (OS) rate of the intention-to-treat (ITT) population is 76.
RELIANCE studies the one-year OS rate to help patients benefit from long-term survival 3.
-
Science Sub-Journal (IF=18) Pan Jingxuan/Jin Yanli Discovered Potential Targeted Therapy Strategies for Chronic Myeloid Leukemia
Time of Update: 2021-10-11
THZ1 (Cyclin-dependent kinase 7 (CDK7) inhibitor) disrupts the transcription of SE-related genes and can effectively eradicate LSC in CML mice driven by retrovirus BCR-ABL, while retaining normal hematopoietic stem cells .
-
2021 IMW Expert Interview｜Professor Bao Li: There are still challenges in the treatment of elderly MM, and new drug solutions are worthy of further exploration
Time of Update: 2021-10-11
Professor Bao Li at this IMW conference, we announced a comparison of two three-drug combination regimens for the treatment of elderly (age> 65 years old) and poor physical condition (IMWG frailty score> 2 or Mayo Clinic Frattyy score for frailty) The results of the study of newly treated MM patients .
-
ESMO2021 Chinese speaker comprehensively summarizes important research on hematological tumors of this conference
Time of Update: 2021-10-11
Sun Mingyuan and Professor Wang Jianxiang from the Hematology Hospital of the Chinese Academy of Medical Sciences to summarize the important research results of hematological tumors announced at this ESMO annual meeting, including his team The research results of Ivosidenib in relapsed or refractory acute myeloid leukemia (R/R AML) carrying IDH1 mutation were reported at the annual meeting .
-
How to identify and treat MGRS?
Time of Update: 2021-10-11
Although most MGRS are not life-threatening except for immunoglobulin-associated (AIg) amyloidosis and monoclonal immunoglobulin deposition disease (MIDD) with extra-renal manifestations, kidney diseases secondary to MGRS may progress, leading to The death of some MGRS patients .
-
Bortezomib induction, high-dose melphalan and lenalidomide maintenance treatment for myeloma patients under 70 years old
Time of Update: 2021-10-11
Mai, Director of the Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Professor of Springer Healthcare The following research background for myeloma patients is the intensive pre-treatment of newly diagnosed multiple myeloma (MM), including induction therapy (IT), high-dose melphalan (MEL200) and autologous blood stem cell transplantation (ASCT), followed by consolidation and/or Maintenance treatment, these treatment research data focus on patients under 65 years of age .
-
Professor Ying Zhitao talks about CAR-T treatment
Time of Update: 2021-10-11
In order to help friends who missed the live broadcast to understand CAR-T cell therapy, the editor summarizes the knowledge content shared by Professor Ying Zhitao for your reference .
-
Lancet Haemat: All-trans retinoic acid + high-dose dexamethasone may become a new first-line therapy for primary immune thrombocytopenia!
Time of Update: 2021-10-10
All-trans retinoic acid combined with high-dose dexamethasone is safe in the treatment of newly diagnosed patients with primary immune thrombocytopenia, and can provide continuous remission.
All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial .
-
Zhao Yanmin, Zhejiang University, etc.: Eltrombopag successfully treats refractory pure red blood cell aplastic anemia after allogeneic hematopoietic stem cell transplantation with ABO blood group incompatibility
Time of Update: 2021-10-10
B2000532 The essential guide of this article: Full text download address: http:// B2000532 About this journal "Journal of Zhejiang University (English Edition) Series B: Biomedicine and Biotechnology", referred to as JZUS-B, is a comprehensive English monthly publication of biology .
-
HAEMOPHILIA: All-cause mortality and causes of death in patients with hemophilia: systematic review and META analysis
Time of Update: 2021-10-10
However, bleeding is still the main cause of death that requires further attentionWith the advancement of treatment, the mortality rate of PWH has declined in the past few decades and is close to the mortality rate of the general population.
-
BJ Haem: Proof of the safety of iron supplementation during pregnancy for mild β-thalassemia
Time of Update: 2021-10-10
In pregnant women with mild β-thalassemia, hepcidin functions normally to maintain iron homeostasis, and iron supplementation is effective and safe .
In pregnant women with mild β-thalassemia, hepcidin functions normally to maintain iron homeostasis, and iron supplementation is effective and safe .
-
JCSM: Iron carboxymaltose can effectively correct iron deficiency in patients with pulmonary hypertension
Time of Update: 2021-10-10
Clinical status, reducing hospitalization rate For patients with pulmonary hypertension with iron deficiency, in addition to the treatment of PAH, it seems feasible and safe to correct iron deficiency through FCM parenteral iron supplementation, and it has a continuous beneficial effect on iron status.
-
AJH: Predictors of mortality and outcome of liver transplantation in spinous erythrocyte hemolytic anemia
Time of Update: 2021-10-10
child In summary, SCHA was associated with a large amount of additional mortality predicted than MELD-Na or Childhood Turbocott-pugh scores, and was consistently resolved in liver transplantation without recurrence .
-
BLOOD: Menin-MLL1 interaction is molecularly dependent on nup98 rearrangement of AML
Time of Update: 2021-10-10
These c-terminal partners include epigenetic modifications and transcription factors with homeobox domains, such as HOX genes, and are associated with acute The poor prognosis of myeloid leukemia (AML) is related .
-
Ann Intern Med: Patients with venous thromboembolism prolong the risk of major bleeding during oral anticoagulation therapy
Time of Update: 2021-10-10
In patients with unprovoked venous thromboembolism for the first time, the long-term risk of major bleeding associated with anticoagulation therapy is greater, and the consequences are relatively serious.
-
Lancet Haemat: The prognosis of children with Down syndrome who develop acute lymphoblastic leukemia
Time of Update: 2021-10-10
Patients with Down syndrome and acute lymphoblastic leukemia have an increased risk of treatment-related mortality and recurrence due to adverse genetic mutations (such as IKZF1 deletion) .
Compared with the control group, Down’s syndrome combined with acute lymphoblastic leukemia is also associated with higher treatment-related mortality (TRM) after induction.
-
HAEMATOLOGICA: Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving single-agent akarabutinib: a pooled analysis of 762 patients.
Time of Update: 2021-10-10
To explore the related effects of acalabutinib on the heart and hypertension of patients with chronic lymphocytic leukemia (CLL) This analysis characterizes the data of CV adverse events (AEs) in CLL patients who received acarabutinib monotherapy in clinical trials (NCT02029443; NCT02475681; NCT02970318; NCT02337829) .
-
HAEMOPHILIA: Post hoc analysis of the long-term response of patients with hemophilia A to fixed-dose prevention of N8-GP
Time of Update: 2021-10-10
Long-term ABR and average factor VIII (FVIII) trough levels were assessed in patients receiving consistent N8-GP prophylaxis every 4 days (Q4D) .
Assess long-term ABR and average factor VIII (FVIII) trough levels in patients receiving consistent N8-GP prevention every 4 days (Q4D).
-
J Clin Oncol: Efficacy of Ibrutinib + Rituximab vs. Placebo + Rituximab in the Treatment of Waldenstrm Macroglobulinemia: Results from the final analysis of the randomized Phase III iNNOVATE study
Time of Update: 2021-10-10
In summary, in the final analysis of the iNNOVATE study with a median follow-up of 50 months, regardless of the MYD88 or CXCR4 mutation status, previous treatment status, and patient characteristics, Ibritinib-rituximab showed superior clinical persistence Benefit .
